Ratings Paxman AB

Equities

PAX

SE0009806284

Delayed Nasdaq Stockholm Other stock markets 10:05:34 2024-06-10 am EDT			5-day change	1st Jan Change
47.5 ^SEK	-1.45%		-0.21%	+29.08%

May. 23	Paxman AB Appoints Karen Giddings Clakely to the Board	CI
May. 23	Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
PAXMAN AB	+29.08%	86.95M	D
ABBOTT LABORATORIES	-1.35%	187B	C+
MEDTRONIC PLC	+1.32%	110B	C
BECTON, DICKINSON AND COMPANY	-1.85%	69.54B	A
CENCORA, INC.	+13.44%	46.37B	B-
DEXCOM, INC.	-6.58%	46.05B	B-
HOYA CORPORATION	+7.97%	42.54B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+18.07%	30.72B	B
TERUMO CORPORATION	+17.70%	25.62B	A-
ZIMMER BIOMET HOLDINGS, INC.	-7.03%	23.32B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders